InsidersTradesSigma
Matinas BioPharma Holdings, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Matinas BioPharma Holdings, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Matinas BioPharma Holdings, Inc. has logged 13 reports. Market capitalisation: €5.3m. The latest transaction was reported on 5 July 2022 (Don). Among the most active insiders: CONRAD HERBERT J. All data is openly available.
13
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
25Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 5 July 2022
Declarations13 total
494,622 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-22-018581:0
7,859 shares0Common StockSEC:0000905718-22-000007:0
6,106 shares0Common StockSEC:0001493152-21-024397:0
462,150 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-21-022716:0
1,280,917 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-21-016565:0
10,244 shares0Common StockSEC:0001493152-21-015878:0
8,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000822:0
4,800 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000828:0
40,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000824:0
6,000 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000830:0
4,800 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000832:0
2,400 shares0Common Stock, par value $0.0001 per shareSEC:0000905718-21-000826:0
50,000 shares0Common Stock, par value $0.0001 per shareSEC:0001493152-21-012764:0
13 of 13 declarations
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. (MTNB) is a U.S.-listed biopharmaceutical company traded on NYSE American, headquartered in Bedminster, New Jersey, United States. Founded in May 2013, the company was built around a clear thesis: improve the delivery of hard-to-formulate anti-infective therapies through its proprietary lipid nanocrystal (LNC) platform, also described in its materials as a cochleate/encochleated delivery approach. For French-speaking investors, this is a classic clinical-stage biotechnology story: high R&D intensity, limited current commercial visibility, and a valuation that depends heavily on clinical, regulatory, and financing milestones. ([matinasbiopharma.com](https://www.matinasbiopharma.com/investors/sec-filings/annual-reports/content/0001493152-23-007726/0001493152-23-007726.pdf?utm_source=openai)) The company’s pipeline is currently centered on two lead programs. MAT2203 is Matinas’ flagship asset: an oral formulation of amphotericin B, a potent antifungal agent that is traditionally administered intravenously. The company is developing MAT2203 to potentially provide a safer, more convenient oral option for serious fungal infections, including invasive aspergillosis. MAT2501 is the second core program: an oral formulation of amikacin aimed at difficult bacterial infections, including nontuberculous mycobacteria (NTM) and other resistant pathogens. Matinas also positions its LNC platform as a broader enabling technology that could support future programs in inflammation and oncology. ([matinasbiopharma.com](https://www.matinasbiopharma.com/lnc-technology/mat2203?utm_source=openai)) From a competitive perspective, Matinas is not a commercial-stage pharmaceutical company with approved products and recurring sales. Instead, it seeks to differentiate itself through drug-delivery innovation in anti-infectives, with the goal of converting IV-only medicines into oral therapies that may reduce toxicity and improve patient convenience. That proposition is scientifically attractive, but execution remains the key risk: the company still depends on clinical data, regulatory interactions, and potential strategic partnerships to advance its pipeline. ([matinasbiopharma.com](https://www.matinasbiopharma.com/investors/news-events/press-releases/detail/248/matinas-biopharmas-lead-antibacterial-development?utm_source=openai)) Recent developments matter materially for the equity story. In April 2026, Matinas disclosed that it had received a notice of non-compliance from NYSE American regarding continued listing standards, tied to stockholders’ equity and a history of losses. During 2025, the company focused mainly on board refreshment and governance changes, while continuing to highlight MAT2203 as its lead program. For investors, this creates a profile with meaningful scientific upside, but also elevated balance-sheet and listing-risk considerations. ([matinasbiopharma.com](https://www.matinasbiopharma.com/investors/sec-filings/all-sec-filings/content/0001493152-26-015170/form8-k.htm?utm_source=openai))
